Clarus Therapeutics (OTCMKTS:CRXTQ) versus Quince Therapeutics (NASDAQ:QNCX) Head-To-Head Comparison

Clarus Therapeutics (OTCMKTS:CRXTQ) and Quince Therapeutics (NASDAQ:QNCX) are both medical companies, but which is the better investment? We will contrast the two companies based on the strength of their valuation, dividends, institutional ownership, risk, earnings, profitability and analyst recommendations.

Institutional & Insider Ownership

30.8% of Quince Therapeutics shares are owned by institutional investors. 5.3% of Clarus Therapeutics shares are owned by insiders. Comparatively, 16.8% of Quince Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Valuation & Earnings

This table compares Clarus Therapeutics and Quince Therapeutics”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Clarus Therapeutics	N/A	N/A	N/A	N/A	N/A
Quince Therapeutics	N/A	N/A	-$31.39 million	($1.24)	-1.16

Profitability

This table compares Clarus Therapeutics and Quince Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Clarus Therapeutics	N/A	N/A	N/A
Quince Therapeutics	N/A	-53.27%	-22.73%

Analyst Recommendations

This is a breakdown of current recommendations for Clarus Therapeutics and Quince Therapeutics, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Clarus Therapeutics	0	0	0	0	0.00
Quince Therapeutics	0	0	4	2	3.33

Quince Therapeutics has a consensus price target of $9.50, suggesting a potential upside of 559.72%. Given Quince Therapeutics’ stronger consensus rating and higher probable upside, analysts plainly believe Quince Therapeutics is more favorable than Clarus Therapeutics.

Summary

Quince Therapeutics beats Clarus Therapeutics on 6 of the 8 factors compared between the two stocks.

About Clarus Therapeutics

Clarus Therapeutics Holdings, Inc., a pharmaceutical company, focuses on the development and commercialization of oral testosterone replacement therapy in the United States. It offers JATENZO, a soft gel oral formulation of testosterone undecanoate for treating hypogonadal men. The company has a licensing agreement with HavaH Therapeutics for product to treat androgen therapies for inflammatory breast disease and certain forms of breast cancer; and license agreement with The Royal Institution for the Advancement of Learning/McGill University to develop and commercialize McGill's proprietary technology designed to treat conditions associated with CoQ10 deficiencies in humans. Clarus Therapeutics Holdings, Inc. was founded in 2003 and is based in Northbrook, Illinois.

About Quince Therapeutics

Quince Therapeutics, Inc., a biopharmaceutical company, focuses on acquiring, developing, and commercializing therapeutics for patients with debilitating and rare diseases. The company's lead asset candidature comprises EryDex for the treatment of rare pediatric neurodegenerative disease, including A-T, an inherited autosomal recessive neurodegenerative and immunodeficiency disorder caused by mutations in ATM gene. Its AIDE technology platform, a drug/device combination platform that uses an automated process to encapsulate a drug into a patient's own red blood cells, as well as consists of an automated equipment the RCL, a sterile single-use consumable treatment kit comprising EryKit, Syringe Kit, drugs, and process solutions. The company was formerly known as Cortexyme, Inc. and changed its name to Quince Therapeutics, Inc. in August 2022. Quince Therapeutics, Inc. was incorporated in 2012 and is headquartered in South San Francisco, California.